Management of Respiratory Syncytial Virus Bronchiolitis: 2015 Survey of Members of the European Society for Paediatric Infectious Diseases
Table 3
Comparison of the use of ribavirin, bronchodilators, and corticosteroids in 1995 with 2015.
Year
Ribavirin
Bronchodilators
Corticosteroids
1995
2015
value
1995
2015
value
1995
2015
value
Number
88
109
88
109
88
109
All patients
0 (0%)
1 (1%)
0.55
54 (61%)
28 (26%)
<0.0001
10 (11%)
7 (6%)
0.17
All high-risk patients
16 (18%)
0 (0%)
<0.0001
15 (17%)
22 (20%)
0.35
23 (26%)
4 (4%)
<0.0001
Selected high-risk patients
34 (39%)
13 (12%)
<0.0001
15 (17%)
39 (36%)
0.0025
38 (43%)
38 (35%)
0.15
Total use (above groups combined)
50 (57%)
14 (13%)
<0.0001
84 (95%)
89 (82%)
0.0024
71 (80%)
49 (45%)
<0.0001
“Selected high-risk patients” means the medication is only advised for some high-risk patients (rather than to every high-risk patient). We did not investigate which subgroups of high-risk patients would receive each of the medications.
